PBP1502 (adalimumab biosimilar) / Prestige BioPharma, Huons - LARVOL DELTA

To Compare the Pharmacokinetics and Safety of PBP1502 and Humira in Healthy Subjects (clinicaltrials.gov) - P1 | N=324 | Recruiting | Sponsor: Prestige Biopharma Limited | Trial completion date: Aug 2023 ➔ Nov 2024 | Trial primary completion date: Mar 2023 ➔ Nov 2024

Trial completion date • Trial primary completion date

Prestige Biopharma, ’Humira similar’ phase 1 approval in Hungary [Google translation] (Korea Medicare) - "Prestige Biopharma...announced...that it had received approval for a global phase 1 clinical trial plan (IND) for Humira biosimilar PBP1502 in Hungary....In this study, about 324 healthy volunteers were randomly administered PBP1502, the original drug sold in the US (US-Humira®), and the original drug sold in Europe (EU-Humira®), and the dynamics and immunogenicity of the drugs were observed. and will evaluate pharmacokinetics and safety."

New P1 trial • Immunology

To Compare the Pharmacokinetics and Safety of PBP1502 and Humira in Healthy Subjects (clinicaltrials.gov) - P1 | N=324 | Recruiting | Sponsor: Prestige Biopharma Limited | Trial completion date: Dec 2022 ➔ Aug 2023 | Trial primary completion date: Aug 2022 ➔ Mar 2023

Trial completion date • Trial primary completion date

To Compare the Pharmacokinetics and Safety of PBP1502 and Humira in Healthy Subjects (clinicaltrials.gov) - P1 | N=324 | Recruiting | Sponsor: Prestige Biopharma Limited | Not yet recruiting ➔ Recruiting

Enrollment open

To Compare the Pharmacokinetics and Safety of PBP1502 and Humira in Healthy Subjects (clinicaltrials.gov) - P1; N=324; Not yet recruiting; Sponsor: Prestige Biopharma Ltd

Clinical • New P1 trial

Huons, Prestige Bio to develop biosimilars (Korea Biomedical Review) - Huons said that it plans to enter the biosimilar market by collaborating with Prestige Bio Pharmaceutical, the Korean branch of Singapore-based Prestige BioPharma. Under an agreement, Huons has secured local exclusive sales rights for HD204, an Avastin Biosimilar, and PBP1502, a Humira Biosimilar."

Licensing / partnership